Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

Lisa Miller interviewed more than two dozen people about the effects weight-loss drugs have had on their romantic ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...

Wall Street is coming off a losing session after the Federal Reserve paused its interest rate-cutting campaign, leaving its ...

Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...